BANGALORE, India -Sun Pharmaceutical Industries Ltd. (524715.BY) said it has received approval from the U.S. Food and Drug Administration to manufacture and sell generic versions of a cancer drug and migraine tablets.
Sun said it shares with other companies 180 days of marketing exclusivity for 50-milligram and 100-mg doses of oxaliplatin injection, a generic version of Sanofi-Aventis U.S. LLC's Eloxatin used in the treatment of colon and rectal cancer.
The drug has annual sales of about $2.3 billion in the U.S., Sun said in a statement late Tuesday.
The company has also received approval for 25-mg, 50-mg and 100-mg doses of sumatriptan succinate tablets, a version of GlaxoSmithkline PLC's (GSK) Imitrex, which is indicated for the treatment of acute migraine.
No comments:
Post a Comment